Sunshine Biopharma Inc.

Shenyang Sunshine Pharmaceuticals Co., Ltd. is a biopharmaceutical enterprise founded in China in 1993. The company is engaged in the production of biological products, including bacterial and virus vaccines and toxoids, and maintains a drug pipeline across various therapeutic areas.

Liaoning Sunshine Bio-Pharmaceutical Company Limited is incorporated in the People's Republic of China and operates within the biopharmaceutical sector, with associated entities engaged in pharmaceutical research, production, sales, and distribution activities.

Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.

PhytoHealth4108 · BiotechTaipei, Taiwan

65% matchPublic

Established in 1998 and headquartered in Taipei, Taiwan, PhytoHealth Corporation specializes in the research, development, production, and commercialization of a diverse portfolio including pharmaceutical products, cosmetic lines, specific over-the-counter medications (Class B), and nutritional supplements. Their prominent offerings feature the PG2 Lyophilized injection, specifically designed to alleviate cancer-related fatigue. The company also markets EnerCharge, available both as a formula to boost physical vigor and maintain mental alertness, and as an energy beverage. Another notable product is ReyeasCleanse health food capsules. Furthermore, PhytoHealth extends its expertise to precision medical devices, specialized diagnostic software, and licensing services for computer-aided diagnostic systems.